Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy-Reference-Cited by-同舟云学术

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy

Published:2021-10-17 Issue:11 Volume:41 Page:1234-1238
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Zheng Yawen¹²,Lai Qinghua¹,Zhao Hanxi²,Li Xiaolin²,Sun Xiaorong²^ORCID,Xing Ligang²

Affiliation:

1. Department of Oncology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University Central hospital affiliated to Shandong First Medical University Jinan Shandong 250013 P. R. China

2. Department of Radiation Oncology, Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong 250117 P. R. China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12227

Reference10 articles.

1. Characteristics and outcomes of patients with metastatic KRAS‐mutant lung adenocarcinomas: the lung cancer mutation consortium experience;El OB;J Thorac Oncol,2019

2. Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non‐small cell lung cancer patients;Liu SY;Biomark Res,2020

3. The prevalence and concurrent pathogenic mutations of KRAS (G12C) in northeast chinese non‐small‐cell lung cancer patients;Liu Y;Cancer Manag Res,2021

4. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer

5. KRAS mutations predict response and outcome in advanced lung adenocarcinoma patients receiving first‐line bevacizumab and platinum‐based chemotherapy;Ghimessy AK;Cancers (Basel),2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolution of resistance to KRASG12C inhibitor in a non-small cell lung cancer responder;2024-01-11

2. Evolution of resistance to KRAS^G12Cinhibitor in a non-small cell lung cancer responder;2023-12-20

3. Non‐small cell lung cancer in China;Cancer Communications;2022-09-08

4. Bioinformatics Analysis for Identifying Differentially Expressed MicroRNAs Derived from Plasma Exosomes Associated with Radiotherapy Resistance in Non-Small-Cell Lung Cancer;Applied Bionics and Biomechanics;2022-05-31